Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
The opportunity: Being part of HSBC in Switzerland, you’ll help evolve and grow our business. The Front Office Customer Due Diligence Advisor is responsible for championing end-to-end CDD activity across onboarding and the client lifecycle, driving faster,
The opportunity: Being part of HSBC in Switzerland, you’ll help evolve and grow our business. The Front Office Customer Due Diligence Advisor is responsible for championing end-to-end CDD activity across onboarding and the client lifecycle, driving faster,
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Job Description SummarySee Job Description. Job Description Workplace: Rotkreuz, Switzerland until 31 December 2027; Basel, Switzerland as of 01 January 2028. Sandoz continues to go through an exciting and transformative period as a global leader and
The opportunity: Being part of HSBC in Switzerland, you’ll help evolve and grow our business. The Front Office Customer Due Diligence Advisor is responsible for championing end-to-end CDD activity across onboarding and the client lifecycle, driving faster,
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a
Overview Regulatory Affairs Intern at Johnson & Johnson, Switzerland | Life Sciences Candidates Job Title: Regulatory Affairs Intern Requisition number: R- About the Company Johnson & Johnson is a global healthcare titan built on the belief